Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:31:17.646Z.
Consensus retrieved: 2026-10-06T11:12:26.159Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:31:17.646Z.
Quote observation: 2026-10-06T18:30:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5ff4a69d5e0bd829addfa263bba904bf87580f902e4d2830b11cef9910c58a28
Forward PE Ratio (N/A) = Dated Quote Price ($2.58) / Consensus Forward EPS ($-0.42)
FORWARD PE RATIO
N/A
Entera Bio Ltd.
Market Cap
$127.42M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Entera Bio Ltd. (ENTX) | $127.42M | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $127.07M | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $125.14M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $123.54M | N/A |
| Pyxis Oncology, Inc. (PYXS)vs › | $129.88M | N/A |
| Cibus, Inc. (CBUS)vs › | $122.13M | N/A |
| Seer, Inc. (SEER)vs › | $121.23M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.92M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $120.76M | N/A |
| Health Catalyst, Inc. (HCAT)vs › | $132.84M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.58, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.42 | $-0.42 – $-0.42 | 3 | n/m |
| 2027-12-31 | $-0.38 | $-0.38 – $-0.38 | 3 | n/m |
| 2028-12-31 | $-0.40 | $-0.44 – $-0.36 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
